A Phase 3 interventional study of 1 to 4 mg tablets of GSK1278863 and 6 mg GSK1278863 tablet in Anaemia, sponsored by GlaxoSmithKline. Completed at 56 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 5th largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 14th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 355 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 5th largest by enrollment, is one of 6 that started in 2016, is one of 10 in phase 3, and was the 19th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 286 Japanese ND and 50 PD subjects with renal anemia. The study will consist of three cohorts. Cohort 1 and Cohort 3 will consist of ND subjects (Erythropoiesis-Stimulating Agent [ESA] users and ESA non-users) randomized to receive GSK1278863 or epoetin beta pegol in a ratio of 1:1. PD subjects will be enrolled into Cohort 2 and will receive GSK1278863. This study consists of a 4-week screening phase, a 52-week treatment phase (including primary efficacy evaluation period [Weeks 40 to 52]), and a 4-week follow-up phase following the treatment phase. The primary objective of this study is to demonstrate non-inferiority of GSK1278863 to epoetin beta pegol based on mean hemoglobin (Hgb) during the primary efficacy evaluation period in ND subjects. ESA non-users from Cohort 1 will be excluded from the primary efficacy analysis. Study results will be used as pivotal study data for an NDA submitted for GSK1278863 for the treatment of renal anemia in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Dialysis:
Use of ESA:
: Determined at the site using an Hgb analyzer
Gender (screening verification only): Female or male. Females: Not pregnant [demonstrated to be negative for human chorionic gonadotropin (hCG) in urine or serum], not breast-feeding, and meet at least one of the following:
Females of non- are defined as follows:
Exclusion Criteria:
Chronic kidney disease (CKD)-related criteria
Dialysis
Cardiovascular disease-related criteria
Other disease-related criteria
Liver disease (if any of the following occurs):
Concomitant medication and other study treatment-related criteria
General health-related criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams \[mg\] as recommended) dose once daily for 52 weeks.
Drug: 1 to 4 mg tablets of GSK1278863 · Drug: 6 mg GSK1278863 tablet
Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram \[µg\] as recommended) dose once every 2 or 4 weeks for 52 weeks.
Drug: Epoetin beta pegol
Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
Drug: 1 to 4 mg tablets of GSK1278863 · Drug: 6 mg GSK1278863 tablet
7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants
The mean hemoglobin during the primary efficacy evaluation period in ND participants was estimated by a statistical model using Mixed Model Repeated Measures (MMRM).
Time frame: Weeks 40 to 52
Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)
ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period were summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.
Time frame: Weeks 40 to 52
Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)
The percentage of ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period was summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.
Time frame: Weeks 40 to 52
Change From Baseline in Hgb at Week 4 in ND Participants
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at Week 4 in ND participants is presented.
Time frame: Baseline (Day 1) and Week 4
Change From Baseline in Hgb at Week 4 in PD Participants
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at week 4 in PD participants is presented.
Time frame: Baseline (Day 1) and Week 4
Number of ND Participants by Hgb Change From Baseline Category at Week 4
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
Time frame: Baseline (Day 1) and Week 4
Percentage of ND Participants by Hgb Change From Baseline Category at Week 4
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
Time frame: Baseline (Day 1) and Week 4
Number of PD Participants by Hgb Change From Baseline Category at Week 4
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
Time frame: Baseline (Day 1) and Week 4
Percentage of PD Participants by Hgb Change From Baseline Category at Week 4
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
Time frame: Baseline (Day 1) and Week 4
Daprodustat Dose Level by Visit in ND Participants
Daprodustat dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Epoetin Beta Pegol Dose Level by Visit in ND Participants
Dose of epoetin beta pegol at a scheduled visit was converted to dose per 4 weeks when the dose frequency was every 2 weeks. Epoetin beta pegol dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Daprodustat Dose Level by Visit in PD Participants
Daprodustat dose level at each assessment visit for PD participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Duration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants
The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.
Time frame: Up to Week 52
Duration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants
The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.
Time frame: Up to Week 52
Number of Dose Adjustments in ND Participants
Number of dose adjustments in ND participants is presented.
Time frame: Up to Week 52
Number of Dose Adjustments in PD Participants
Number of dose adjustments in PD participants is presented.
Time frame: Up to Week 52
Hgb Values at Each Assessment Visit in ND Participants
Hgb values at each assessment visit for ND participants is presented.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Hgb Values at Each Assessment Visit in PD Participants
Hgb values at each assessment visit for PD participants is presented.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Change From Baseline in Hgb Values at Each Assessment Visit in ND Participants
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in ND participants is presented.
Time frame: Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Change From Baseline in Hgb Values at Each Assessment Visit in PD Participants
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in PD participants is presented.
Time frame: Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Number of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Number of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Percentage of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Percentage of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Number of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Number of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Percentage of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Percentage of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants
Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).
Time frame: Weeks 40 to 52
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants
Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).
Time frame: Weeks 40 to 52
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants
The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.
Time frame: Up to week 52
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants
The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.
Time frame: Up to week 52
Number of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Number of ND participants who had an Hgb level of less than 7.5 g/dL is presented.
Time frame: Up to week 52
Percentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Percentage of ND participants who had an Hgb level of less than 7.5 g/dL is presented.
Time frame: Up to week 52
Number of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Number of PD participants who had an Hgb level of less than 7.5 g/dL is presented.
Time frame: Up to week 52
Percentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Percentage of PD participants who had an Hgb level of less than 7.5 g/dL is presented.
Time frame: Up to week 52
Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Number of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
Time frame: Up to week 52
Percentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Percentage of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
Time frame: Up to week 52
Number of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Number of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
Time frame: Up to week 52
Percentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Percentage of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
Time frame: Up to week 52
Number of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL
Number of ND participants who had an Hgb level of more than 13.0 g/dL is presented.
Time frame: Up to week 52
Percentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL
Percentage of ND participants who had an Hgb level of more than 13.0 g/dL is presented.
Time frame: Up to week 52
Number of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL
Number of PD participants who had an Hgb level of more than 13.0 g/dL is presented.
Time frame: Up to week 52
Percentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL
Percentage of PD participants who had an Hgb level of more than 13.0 g/dL is presented.
Time frame: Up to week 52
Number of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants
Number of episodes with Hgb level of more than 13.0 g/dL in ND participants is presented.
Time frame: Up to week 52
Number of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants
Number of episodes with Hgb level of more than 13.0 g/dL in PD participants is presented.
Time frame: Up to week 52
Monthly Average Dose of Oral Iron During the Treatment Period in ND Participants
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in ND participants is presented.
Time frame: Up to Week 52
Monthly Average Dose of Oral Iron During the Treatment Period in PD Participants
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in PD participants is presented.
Time frame: Up to Week 52
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in ND participants is presented.
Time frame: Weeks 40 to 52
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in PD participants is presented.
Time frame: Weeks 40 to 52
Number of ND Participants Who Used Oral Iron During the Treatment Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the treatment period were summarized.
Time frame: Up to week 52
Number of PD Participants Who Used Oral Iron During the Treatment Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the treatment period were summarized.
Time frame: Up to week 52
Percentage of ND Participants Who Used Oral Iron During the Treatment Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the treatment period were summarized.
Time frame: Up to week 52
Percentage of PD Participants Who Used Oral Iron During the Treatment Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the treatment period were summarized.
Time frame: Up to week 52
Number of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
Time frame: Weeks 40 to 52
Number of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
Time frame: Weeks 40 to 52
Percentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
Time frame: Weeks 40 to 52
Percentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
Time frame: Weeks 40 to 52
Change From Baseline in Ferritin in ND Participants
Change from Baseline in Ferritin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Change From Baseline in Ferritin in PD Participants
Change from Baseline in Ferritin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Percent Change From Baseline in Transferrin Saturation (TSAT) in ND Participants
Percent change from Baseline in TSAT in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Percent Change From Baseline in TSAT in PD Participants
Percent change from Baseline in TSAT in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Percent Change From Baseline in Hepcidin in ND Participants
Percent change from Baseline in Hepcidin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Percent Change From Baseline in Hepcidin in PD Participants
Percent change from Baseline in Hepcidin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Change From Baseline in Serum Iron in ND Participants
Change from Baseline in serum iron in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Change From Baseline in Serum Iron in PD Participants
Change from Baseline in serum iron in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Change From Baseline in Total Iron Binding Capacity (TIBC) in ND Participants
Change from Baseline in TIBC in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Change From Baseline in TIBC in PD Participants
Change from Baseline in TIBC in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Area Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants
Blood samples were collected at indicated timepoints. Pharmacokinetic (PK) parameters of Daprodustat were calculated using non-compartmental method. AUC (0-4) is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.
Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Maximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants
Blood samples were collected at indicated timepoints. PK parameters of Daprodustat were calculated using non-compartmental method. Cmax is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.
Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24
This was an open-label, active-controlled, parallel-group, multi-center study to compare the efficacy (verification of non-inferiority) and safety of GSK1278863 (daprodustat) versus epoetin beta pegol in Japanese non-dialysis (ND) participants, including an open-label non-comparative cohort of peritoneal dialysis (PD) participants.
| Milestone | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants |
|---|---|---|---|
| Started | 149 | 150 | 56 |
| Completed | 111 | 113 | 43 |
| Not completed | 38 | 37 | 13 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Needs maintenance/changes in dialysis | 16 | 19 | 5 |
| Withdrew: Cancer event | 1 | 3 | 0 |
| Withdrew: Participant had renal transplant | 3 | 0 | 0 |
| Withdrew: Met hemoglobin stopping criteria | 1 | 0 | 0 |
| Withdrew: Adverse event | 12 | 13 | 7 |
The mean hemoglobin during the primary efficacy evaluation period in ND participants was estimated by a statistical model using Mixed Model Repeated Measures (MMRM).
| Grams per deciliter (g/dL) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants | 11.97 ± 0.061 | 11.86 ± 0.063 |
ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period were summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Responder | 81 | 80 |
| Non-Responder | 7 | 7 |
The percentage of ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period was summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Responder | 92 | 92 |
| Non-Responder | 8 | 8 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at Week 4 in ND participants is presented.
| g/dL | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Change From Baseline in Hgb at Week 4 in ND Participants | 0.47 ± 0.878 | 0.26 ± 0.711 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at week 4 in PD participants is presented.
| g/dL | Daprodustat in PD Participants |
|---|---|
| Change From Baseline in Hgb at Week 4 in PD Participants | -0.09 ± 0.899 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| <=-2.0 | 1 | 2 |
| >-2.0 and <=-1.0 | 4 | 3 |
| >-1.0 and <=0 | 28 | 33 |
| >0 and <=1.0 | 43 | 56 |
| >1.0 and <=2.0 | 29 | 15 |
| >2.0 | 2 | 0 |
| within +/- 1.0 | 72 | 90 |
| over +/- 2.0 | 3 | 1 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| <=-2.0 | 1 | 2 |
| >-2.0 and <=-1.0 | 4 | 3 |
| >-1.0 and <=0 | 26 | 30 |
| >0 and <=1.0 | 40 | 51 |
| >1.0 and <=2.0 | 27 | 14 |
| >2.0 | 2 | 0 |
| within +/- 1.0 | 67 | 83 |
| over +/- 2.0 | 3 | 1 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
| Participants | Daprodustat in PD Participants |
|---|---|
| <=-2.0 | 0 |
| >-2.0 and <=-1.0 | 10 |
| >-1.0 and <=0 | 20 |
| >0 and <=1.0 | 20 |
| >1.0 and <=2.0 | 4 |
| >2.0 | 1 |
| within +/- 1.0 | 41 |
| over +/- 2.0 | 1 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.
| Percentage of Participants | Daprodustat in PD Participants |
|---|---|
| <=-2.0 | 0 |
| >-2.0 and <=-1.0 | 18 |
| >-1.0 and <=0 | 36 |
| >0 and <=1.0 | 36 |
| >1.0 and <=2.0 | 7 |
| >2.0 | 2 |
| within +/- 1.0 | 75 |
| over +/- 2.0 | 2 |
Daprodustat dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
| Milligrams per day (mg/day) | Daprodustat in ND Participants |
|---|---|
| Day 1, n=108 | 4.0 (2.0 to 4.0) |
| Week 4, n=106 | 4.0 (2.0 to 6.0) |
| Week 8, n=106 | 4.0 (2.0 to 6.0) |
| Week 12, n=106 | 4.0 (2.0 to 6.0) |
| Week 16, n=103 | 4.0 (2.0 to 6.0) |
| Week 20, n=100 | 4.0 (2.0 to 8.0) |
| Week 24, n=96 | 4.0 (2.0 to 8.0) |
| Week 28, n=94 | 4.0 (2.0 to 8.0) |
| Week 32, n=92 | 4.0 (2.0 to 6.0) |
| Week 36, n=89 | 4.0 (2.0 to 6.0) |
| Week 40, n=88 | 4.0 (2.0 to 6.0) |
| Week 44, n=88 | 4.0 (2.0 to 7.0) |
| Week 48, n=87 | 4.0 (2.0 to 6.0) |
Dose of epoetin beta pegol at a scheduled visit was converted to dose per 4 weeks when the dose frequency was every 2 weeks. Epoetin beta pegol dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
| Micrograms per 4 weeks | Epoetin Beta Pegol in ND Participants |
|---|---|
| Day 1, n=109 | 50.0 (50.0 to 50.0) |
| Week 4, n=109 | 75.0 (50.0 to 100.0) |
| Week 8, n=107 | 100.0 (50.0 to 100.0) |
| Week 12, n=105 | 100.0 (50.0 to 150.0) |
| Week 16, n=104 | 75.0 (25.0 to 150.0) |
| Week 20, n=100 | 75.0 (50.0 to 150.0) |
| Week 24, n=97 | 75.0 (50.0 to 150.0) |
| Week 28, n=92 | 75.0 (50.0 to 150.0) |
| Week 32, n=90 | 75.0 (50.0 to 150.0) |
| Week 36, n=88 | 75.0 (75.0 to 150.0) |
| Week 40, n=87 | 75.0 (50.0 to 150.0) |
| Week 44, n=84 | 100.0 (62.5 to 150.0) |
| Week 48, n=82 | 100.0 (75.0 to 150.0) |
Daprodustat dose level at each assessment visit for PD participants is presented using 25th percentile (P25), median, and 75th percentile (P75).
| mg/day | Daprodustat in PD Participants |
|---|---|
| Day 1, n=55 | 4.0 (4.0 to 4.0) |
| Week 4, n=55 | 6.0 (4.0 to 6.0) |
| Week 8, n=52 | 6.0 (4.0 to 8.0) |
| Week 12, n=52 | 6.0 (4.0 to 8.0) |
| Week 16, n=51 | 6.0 (4.0 to 8.0) |
| Week 20, n=50 | 6.0 (4.0 to 12.0) |
| Week 24, n=48 | 8.0 (4.0 to 12.0) |
| Week 28, n=45 | 8.0 (4.0 to 8.0) |
| Week 32, n=45 | 6.0 (4.0 to 8.0) |
| Week 36, n=45 | 8.0 (4.0 to 12.0) |
| Week 40, n=44 | 6.0 (2.0 to 8.0) |
| Week 44, n=43 | 6.0 (2.0 to 8.0) |
| Week 48, n=43 | 6.0 (2.0 to 8.0) |
The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.
| Days | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Duration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants | 28.0 (14 to 111) | 28.0 (26 to 113) |
The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.
| Days | Daprodustat in PD Participants |
|---|---|
| Duration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants | 28.0 (19 to 168) |
Number of dose adjustments in ND participants is presented.
| Number of dose adjustments | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of Dose Adjustments in ND Participants | 5.0 (0 to 9) | 6.0 (1 to 10) |
Number of dose adjustments in PD participants is presented.
| Number of dose adjustments | Daprodustat in PD Participants |
|---|---|
| Number of Dose Adjustments in PD Participants | 5.0 (0 to 11) |
Hgb values at each assessment visit for ND participants is presented.
| g/dL | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Day 1, n=108,109 | 10.48 ± 1.140 | 10.68 ± 1.066 |
| Week 4, n=107,109 | 10.95 ± 1.122 | 10.94 ± 1.024 |
| Week 8, n=107,109 | 11.19 ± 1.092 | 11.34 ± 0.905 |
| Week 12, n=106,107 | 11.51 ± 1.024 | 11.84 ± 0.880 |
| Week 16, n=104,105 | 11.90 ± 1.091 | 12.07 ± 1.073 |
| Week 20, n=102,103 | 11.84 ± 0.909 | 11.96 ± 0.820 |
| Week 24, n=99,99 | 11.87 ± 0.740 | 11.80 ± 0.855 |
| Week 28, n=96,93 | 11.98 ± 0.845 | 11.83 ± 0.859 |
| Week 32, n=92,90 | 12.03 ± 0.785 | 11.80 ± 0.875 |
| Week 36, n=92,88 | 11.93 ± 0.730 | 11.81 ± 0.810 |
| Week 40, n=88,87 | 11.88 ± 0.735 | 12.00 ± 0.857 |
| Week 44, n=88,86 | 11.87 ± 0.868 | 11.75 ± 0.763 |
| Week 48, n=87,83 | 12.05 ± 0.896 | 11.80 ± 0.904 |
| Week 52, n=87,81 | 12.01 ± 1.003 | 11.99 ± 0.930 |
Hgb values at each assessment visit for PD participants is presented.
| g/dL | Daprodustat in PD Participants |
|---|---|
| Day 1, n=55 | 10.85 ± 0.964 |
| Week 4, n=55 | 10.77 ± 1.239 |
| Week 8, n=54 | 10.83 ± 1.259 |
| Week 12, n=52 | 11.36 ± 1.097 |
| Week 16, n=51 | 11.42 ± 1.079 |
| Week 20, n=50 | 11.54 ± 0.807 |
| Week 24, n=49 | 11.69 ± 0.816 |
| Week 28, n=48 | 11.95 ± 1.038 |
| Week 32, n=45 | 12.07 ± 0.890 |
| Week 36, n=45 | 11.90 ± 0.839 |
| Week 40, n=44 | 12.12 ± 0.795 |
| Week 44, n=43 | 11.92 ± 0.824 |
| Week 48, n=43 | 12.10 ± 0.774 |
| Week 52, n=43 | 12.12 ± 0.699 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in ND participants is presented.
| g/dL | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=107,109 | 0.47 ± 0.878 | 0.26 ± 0.711 |
| Week 8, n=107,109 | 0.71 ± 1.122 | 0.66 ± 1.109 |
| Week 12, n=106,107 | 1.04 ± 1.352 | 1.18 ± 1.384 |
| Week 16, n=104,105 | 1.45 ± 1.376 | 1.40 ± 1.495 |
| Week 20, n=102,103 | 1.39 ± 1.330 | 1.26 ± 1.336 |
| Week 24, n=99,99 | 1.41 ± 1.346 | 1.10 ± 1.295 |
| Week 28, n=96,93 | 1.54 ± 1.375 | 1.08 ± 1.151 |
| Week 32, n=92,90 | 1.60 ± 1.371 | 1.04 ± 1.299 |
| Week 36, n=92,88 | 1.49 ± 1.265 | 1.04 ± 1.294 |
| Week 40, n=88,87 | 1.44 ± 1.371 | 1.26 ± 1.304 |
| Week 44, n=88,86 | 1.43 ± 1.435 | 1.01 ± 1.131 |
| Week 48, n=87,83 | 1.61 ± 1.350 | 1.03 ± 1.172 |
| Week 52, n=87,81 | 1.56 ± 1.527 | 1.21 ± 1.432 |
Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in PD participants is presented.
| g/dL | Daprodustat in PD Participants |
|---|---|
| Week 4, n=55 | -0.09 ± 0.899 |
| Week 8, n=54 | -0.06 ± 1.127 |
| Week 12, n=52 | 0.44 ± 1.173 |
| Week 16, n=51 | 0.52 ± 1.295 |
| Week 20, n=50 | 0.63 ± 1.158 |
| Week 24, n=49 | 0.74 ± 1.182 |
| Week 28, n=48 | 1.00 ± 1.317 |
| Week 32, n=45 | 1.13 ± 1.192 |
| Week 36, n=45 | 0.95 ± 1.106 |
| Week 40, n=44 | 1.13 ± 1.227 |
| Week 44, n=43 | 0.90 ± 1.093 |
| Week 48, n=43 | 1.08 ± 1.248 |
| Week 52, n=43 | 1.10 ± 1.226 |
Number of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Day 1, n=108,109 | 29 | 36 |
| Week 4, n=107,109 | 43 | 48 |
| Week 8, n=107,109 | 64 | 73 |
| Week 12, n=106,107 | 78 | 85 |
| Week 16, n=104,105 | 84 | 80 |
| Week 20, n=102,103 | 88 | 85 |
| Week 24, n=99,99 | 86 | 85 |
| Week 28, n=96,93 | 77 | 73 |
| Week 32, n=92,90 | 79 | 67 |
| Week 36, n=92,88 | 79 | 70 |
| Week 40, n=88,87 | 78 | 72 |
| Week 44, n=88,86 | 71 | 68 |
| Week 48, n=87,83 | 75 | 62 |
| Week 52, n=87,81 | 67 | 59 |
Percentage of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
| Percentage of Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Day 1, n=108,109 | 27 | 33 |
| Week 4, n=107,109 | 40 | 44 |
| Week 8, n=107,109 | 60 | 67 |
| Week 12, n=106,107 | 74 | 79 |
| Week 16, n=104,105 | 81 | 76 |
| Week 20, n=102,103 | 86 | 83 |
| Week 24, n=99,99 | 87 | 86 |
| Week 28, n=96,93 | 80 | 78 |
| Week 32, n=92,90 | 86 | 74 |
| Week 36, n=92,88 | 86 | 80 |
| Week 40, n=88,87 | 89 | 83 |
| Week 44, n=88,86 | 81 | 79 |
| Week 48, n=87,83 | 86 | 75 |
| Week 52, n=87,81 | 77 | 73 |
Number of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
| Participants | Daprodustat in PD Participants |
|---|---|
| Day 1, n=55 | 28 |
| Week 4, n=55 | 25 |
| Week 8, n=54 | 26 |
| Week 12, n=52 | 32 |
| Week 16, n=51 | 32 |
| Week 20, n=50 | 38 |
| Week 24, n=49 | 36 |
| Week 28, n=48 | 39 |
| Week 32, n=45 | 34 |
| Week 36, n=45 | 36 |
| Week 40, n=44 | 34 |
| Week 44, n=43 | 33 |
| Week 48, n=43 | 36 |
| Week 52, n=43 | 38 |
Percentage of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.
| Percentage of Participants | Daprodustat in PD Participants |
|---|---|
| Day 1, n=55 | 51 |
| Week 4, n=55 | 45 |
| Week 8, n=54 | 48 |
| Week 12, n=52 | 62 |
| Week 16, n=51 | 63 |
| Week 20, n=50 | 76 |
| Week 24, n=49 | 73 |
| Week 28, n=48 | 81 |
| Week 32, n=45 | 76 |
| Week 36, n=45 | 80 |
| Week 40, n=44 | 77 |
| Week 44, n=43 | 77 |
| Week 48, n=43 | 84 |
| Week 52, n=43 | 88 |
Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).
| Percentage of time | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants | 85.44 ± 22.473 | 80.57 ± 25.973 |
Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).
| Percentage of time | Daprodustat in PD Participants |
|---|---|
| Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants | 85.73 ± 19.974 |
The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.
| Days | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Time to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants | 58.0 (29.0 to 87.0) | 57.0 (29.0 to 85.0) |
The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.
| Days | Daprodustat in PD Participants |
|---|---|
| Time to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants | 84.0 (29.0 to 141.0) |
Number of ND participants who had an Hgb level of less than 7.5 g/dL is presented.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL | 1 | 0 |
Percentage of ND participants who had an Hgb level of less than 7.5 g/dL is presented.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL | 1 | 0 |
Number of PD participants who had an Hgb level of less than 7.5 g/dL is presented.
| Participants | Daprodustat in PD Participants |
|---|---|
| Number of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL | 0 |
Percentage of PD participants who had an Hgb level of less than 7.5 g/dL is presented.
| Percentage of participants | Daprodustat in PD Participants |
|---|---|
| Percentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL | 0 |
Number of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | 17 | 11 |
Percentage of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | 16 | 10 |
Number of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
| Participants | Daprodustat in PD Participants |
|---|---|
| Number of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | 11 |
Percentage of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
| Percentage of participants | Daprodustat in PD Participants |
|---|---|
| Percentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | 20 |
Number of ND participants who had an Hgb level of more than 13.0 g/dL is presented.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL | 49 | 52 |
Percentage of ND participants who had an Hgb level of more than 13.0 g/dL is presented.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL | 45 | 48 |
Number of PD participants who had an Hgb level of more than 13.0 g/dL is presented.
| Participants | Daprodustat in PD Participants |
|---|---|
| Number of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL | 28 |
Percentage of PD participants who had an Hgb level of more than 13.0 g/dL is presented.
| Percentage of participants | Daprodustat in PD Participants |
|---|---|
| Percentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL | 51 |
Number of episodes with Hgb level of more than 13.0 g/dL in ND participants is presented.
| Episodes | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants | 76 | 88 |
Number of episodes with Hgb level of more than 13.0 g/dL in PD participants is presented.
| Episodes | Daprodustat in PD Participants |
|---|---|
| Number of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants | 43 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in ND participants is presented.
| Milligrams | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Monthly Average Dose of Oral Iron During the Treatment Period in ND Participants | 837.37 ± 1209.100 | 747.04 ± 1130.767 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in PD participants is presented.
| Milligrams | Daprodustat in PD Participants |
|---|---|
| Monthly Average Dose of Oral Iron During the Treatment Period in PD Participants | 2468.68 ± 5418.767 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in ND participants is presented.
| Milligrams | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants | 967.41 ± 1854.896 | 777.69 ± 1639.331 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in PD participants is presented.
| Milligrams | Daprodustat in PD Participants |
|---|---|
| Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants | 3038.67 ± 6239.034 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the treatment period were summarized.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of ND Participants Who Used Oral Iron During the Treatment Period | 56 | 49 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the treatment period were summarized.
| Participants | Daprodustat in PD Participants |
|---|---|
| Number of PD Participants Who Used Oral Iron During the Treatment Period | 33 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the treatment period were summarized.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of ND Participants Who Used Oral Iron During the Treatment Period | 52 | 45 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the treatment period were summarized.
| Percentage of participants | Daprodustat in PD Participants |
|---|---|
| Percentage of PD Participants Who Used Oral Iron During the Treatment Period | 60 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
| Participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Number of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period | 34 | 28 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
| Participants | Daprodustat in PD Participants |
|---|---|
| Number of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period | 22 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
| Percentage of participants | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Percentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period | 39 | 32 |
Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.
| Percentage of participants | Daprodustat in PD Participants |
|---|---|
| Percentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period | 50 |
Change from Baseline in Ferritin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
| Micrograms per liter (µg/L) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=107,109 | -41.4 (-53.7 to -29.2) | -29.0 (-41.1 to -16.9) |
| Week 16, n=104,105 | -83.4 (-102.8 to -64.0) | -29.3 (-48.6 to -10.0) |
| Week 28, n=96,93 | -80.1 (-96.4 to -63.8) | -16.6 (-33.1 to -0.1) |
| Week 40, n=88,87 | -56.3 (-79.1 to -33.4) | -16.0 (-38.9 to 6.9) |
| Week 52, n=87,81 | -42.7 (-68.9 to -16.4) | -14.0 (-40.9 to 13.0) |
Change from Baseline in Ferritin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
| µg/L | Daprodustat in PD Participants |
|---|---|
| Week 4, n=55 | -36.4 (-49.8 to -23.1) |
| Week 16, n=51 | -81.8 (-103.7 to -59.9) |
| Week 28, n=48 | -89.1 (-111.6 to -66.7) |
| Week 40, n=44 | -74.6 (-112.7 to -36.4) |
| Week 52, n=43 | -63.6 (-101.0 to -26.2) |
Percent change from Baseline in TSAT in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
| Percent change | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=107,109 | -12.4 (-17.6 to -6.8) | -5.4 (-11.1 to 0.5) |
| Week 16, n=104,105 | -16.3 (-21.6 to -10.6) | -0.3 (-6.6 to 6.5) |
| Week 28, n=96,93 | -17.5 (-23.2 to -11.4) | 10.6 (2.9 to 18.9) |
| Week 40, n=88,87 | -11.2 (-17.8 to -4.1) | 12.5 (4.1 to 21.5) |
| Week 52, n=87,81 | -11.7 (-18.3 to -4.6) | 7.0 (-1.3 to 15.9) |
Percent change from Baseline in TSAT in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
| Percent change | Daprodustat in PD Participants |
|---|---|
| Week 4, n=55 | -19.2 (-27.2 to -10.4) |
| Week 16, n=51 | -29.1 (-36.9 to -20.5) |
| Week 28, n=48 | -22.6 (-30.4 to -14.0) |
| Week 40, n=44 | -19.5 (-28.3 to -9.5) |
| Week 52, n=43 | -14.7 (-25.4 to -2.6) |
Percent change from Baseline in Hepcidin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
| Percent change | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=99,100 | -49.13 (-54.63 to -42.97) | -19.20 (-27.82 to -9.55) |
| Week 16, n=86,99 | -55.67 (-61.60 to -48.82) | -3.73 (-15.95 to 10.27) |
| Week 28, n=81,85 | -56.67 (-62.53 to -49.90) | 7.61 (-6.75 to 24.18) |
| Week 40, n=76,80 | -47.77 (-55.10 to -39.23) | 9.54 (-5.62 to 27.12) |
| Week 52, n=76,74 | -45.27 (-54.32 to -34.43) | 10.13 (-8.27 to 32.21) |
Percent change from Baseline in Hepcidin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
| Percent change | Daprodustat in PD Participants |
|---|---|
| Week 4, n=53 | -49.79 (-58.57 to -39.15) |
| Week 16, n=48 | -62.59 (-69.95 to -53.42) |
| Week 28, n=39 | -65.37 (-72.61 to -56.22) |
| Week 40, n=39 | -67.91 (-76.10 to -56.91) |
| Week 52, n=40 | -54.77 (-66.82 to -38.33) |
Change from Baseline in serum iron in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
| Micromoles per liter (µmol/L) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=107,109 | 0.5 (-0.6 to 1.5) | -0.8 (-1.8 to 0.2) |
| Week 16, n=104,105 | 0.3 (-0.8 to 1.3) | 0.6 (-0.4 to 1.6) |
| Week 28, n=96,93 | 0.3 (-0.8 to 1.5) | 2.0 (0.8 to 3.1) |
| Week 40, n=88,87 | 0.9 (-0.2 to 2.1) | 1.8 (0.6 to 2.9) |
| Week 52, n=87,81 | 0.7 (-0.4 to 1.8) | 1.1 (-0.1 to 2.2) |
Change from Baseline in serum iron in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
| µmol/L | Daprodustat in PD Participants |
|---|---|
| Week 4, n=55 | -1.2 (-2.7 to 0.4) |
| Week 16, n=51 | -2.4 (-3.8 to -1.1) |
| Week 28, n=48 | -1.0 (-2.5 to 0.5) |
| Week 40, n=44 | -0.4 (-1.9 to 1.2) |
| Week 52, n=43 | 1.0 (-1.9 to 3.9) |
Change from Baseline in TIBC in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
| µmol/L | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants |
|---|---|---|
| Week 4, n=107,109 | 6.9 (6.2 to 7.7) | 0.5 (-0.2 to 1.3) |
| Week 16, n=104,105 | 9.9 (8.7 to 11.0) | 1.9 (0.8 to 3.1) |
| Week 28, n=96,93 | 9.9 (8.7 to 11.1) | 1.4 (0.2 to 2.6) |
| Week 40, n=88,87 | 8.0 (6.6 to 9.4) | 0.2 (-1.2 to 1.7) |
| Week 52, n=87,81 | 7.8 (6.3 to 9.3) | 0.1 (-1.4 to 1.7) |
Change from Baseline in TIBC in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.
| µmol/L | Daprodustat in PD Participants |
|---|---|
| Week 4, n=55 | 6.9 (5.7 to 8.0) |
| Week 16, n=51 | 9.5 (7.7 to 11.3) |
| Week 28, n=48 | 11.0 (8.8 to 13.2) |
| Week 40, n=44 | 11.0 (8.0 to 14.0) |
| Week 52, n=43 | 9.6 (6.8 to 12.5) |
Blood samples were collected at indicated timepoints. Pharmacokinetic (PK) parameters of Daprodustat were calculated using non-compartmental method. AUC (0-4) is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.
| Hour*nanogram per milliliter | Daprodustat 1 mg | Daprodustat 2 mg | Daprodustat 4 mg | Daprodustat 6 mg | Daprodustat 8 mg | Daprodustat 12 mg | Daprodustat 18 mg | Daprodustat 24 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants | 35.3199 ± 38.4 | 63.0175 ± 89.8 | 101.9293 ± 96.5 | 152.4966 ± 83.2 | 167.6515 ± 105.9 | 190.0962 ± 65.9 | 435.6847 ± 131.7 | 404.0567 ± NA |
Blood samples were collected at indicated timepoints. PK parameters of Daprodustat were calculated using non-compartmental method. Cmax is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.
| Nanogram per milliliter | Daprodustat 1 mg | Daprodustat 2 mg | Daprodustat 4 mg | Daprodustat 6 mg | Daprodustat 8 mg | Daprodustat 12 mg | Daprodustat 18 mg | Daprodustat 24 mg |
|---|---|---|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants | 17.6522 ± 36.5 | 35.0709 ± 91.2 | 58.6098 ± 83.2 | 81.1851 ± 82.6 | 91.0731 ± 95.4 | 94.1242 ± 73.3 | 197.9290 ± 159.6 | 226.0000 ± NA |
Collected over On-therapy serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment up to Week 52 for both ND and PD participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daprodustat in ND Participants | 1/149 (0.7%) | 34/149 (22.8%) | 85/149 (57%) |
| Epoetin Beta Pegol in ND Participants | 2/150 (1.3%) | 43/150 (28.7%) | 91/150 (60.7%) |
| Daprodustat in PD Participants | 0/56 (0%) | 26/56 (46.4%) | 41/56 (73.2%) |
| Event | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants |
|---|---|---|---|
| PeritonitisInfections and infestations | 0/149 | 0/150 | 9/56 |
| Renal impairmentRenal and urinary disorders | 5/149 | 11/150 | 0/56 |
| Cardiac failure congestiveCardiac disorders | 0/149 | 5/150 | 3/56 |
| Chronic kidney diseaseRenal and urinary disorders | 6/149 | 8/150 | 0/56 |
| End stage renal diseaseRenal and urinary disorders | 3/149 | 0/150 | 0/56 |
| Cardiac failureCardiac disorders | 0/149 | 1/150 | 1/56 |
| Prinzmetal anginaCardiac disorders | 0/149 | 0/150 | 1/56 |
| DehydrationMetabolism and nutrition disorders | 0/149 | 2/150 | 1/56 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/149 | 0/150 | 1/56 |
| DiarrhoeaGastrointestinal disorders | 0/149 | 0/150 | 1/56 |
| Event | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 49/149 | 56/150 | 16/56 |
| Catheter site infectionInfections and infestations | 0/149 | 0/150 | 9/56 |
| DiarrhoeaGastrointestinal disorders | 0/149 | 0/150 | 7/56 |
| ConstipationGastrointestinal disorders | 10/149 | 18/150 | 0/56 |
| NauseaGastrointestinal disorders | 0/149 | 0/150 | 6/56 |
| Device related infectionInfections and infestations | 0/149 | 0/150 | 5/56 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/149 | 0/150 | 5/56 |
| HypertensionVascular disorders | 4/149 | 8/150 | 5/56 |
| PruritusSkin and subcutaneous tissue disorders | 12/149 | 5/150 | 0/56 |
| Back painMusculoskeletal and connective tissue disorders | 11/149 | 11/150 | 4/56 |
| Age, Continuous(Years) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants | Total |
|---|---|---|---|---|
| Mean | 68.2 ± 11.57 | 70.3 ± 9.09 | 64.4 ± 9.64 | 68.5 ± 10.45 |
| Sex: Female, Male(Participants) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants | Total |
|---|---|---|---|---|
| Female | 53 | 58 | 12 | 123 |
| Male | 96 | 92 | 44 | 232 |
| Race/Ethnicity, Customized(Count of Participants) | Daprodustat in ND Participants | Epoetin Beta Pegol in ND Participants | Daprodustat in PD Participants | Total |
|---|---|---|---|---|
| Asian- Japanese Heritage | 149 | 150 | 56 | 355 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2016 to primary completion in Oct 2018, 28 months.
Results were first posted in Nov 2019, 1 year after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 28 months is above that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863